A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants

简要总结

主要结局

次要结局

• Cmax(Up to Day 23)
• Number of participants with vital sign abnormalities(Up to Day 23)
• Area under the plasma concentration-time curve over one dosing interval (AUC(TAU))(Up to Day 23)
• Number of participants with Adverse Events (AEs)(Up to Day 52)
• Number of participants with Severe Adverse Events (SAEs)(Up to Day 52)
• Number of participants with physical examination abnormalities(Up to Day 23)
• Apparent volume of distribution of terminal phase (Vz/F)(Up to Day 23)
• Number of participants with electrocardiogram abnormalities(Up to Day 23)
• Number of participants with clinical safety laboratory test abnormalities(Up to Day 22)
• Apparent terminal phase half-life (T-HALF)(Up to Day 23)
• Apparent total body clearance (CLT/F)(Up to Day 23)
• Trough observed plasma concentration (Ctrough)(Up to Day 23)
• Time of maximum observed plasma concentration (Tmax)(Up to Day 23)